A Phase 1 interventional study of Oligodendrocyte progenitor cell culture/craniotomy in Demyelinating Diseases, sponsored by Rajavithi Hospital. Completed at 1 site in Thailand. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-19.
Sponsored by Rajavithi Hospital · Phase 1, Interventional, and Basic science
Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.
Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.
76 studies on the registry are indexed under Demyelinating Diseases; 27 are open to participants now.
This study's enrollment of 5 is below the median of 48 across 45 interventional studies indexed under Demyelinating Diseases.
Browse Demyelinating Diseases studies →Rajavithi Hospital is the lead sponsor of 46 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
Procedure: Oligodendrocyte progenitor cell culture/craniotomy
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Also known as: Rajavithi Oligodendrocyte progenitor cell culture protocol
Number of oligodendrocyte progenitor cell differentiation
Time frame: one month
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rajavithi Hospital